



#15CongressGECP

Emerging Tobacco Exposure Products in the Context of Tobacco Pandemics

Dra. Cristina Martínez

Institut Català d'Oncologia













DISCLOSURES

Deputy Director of the Tobacco Control Unit, Catalan Institute of Oncology Associate Lecturer - Nursing Faculty, University of Barcelona Tobacco control research funded by Spanish and European Agencies No links with pharmaceutical, tobacco/e-cigarette companies The Congress Lung Cancer 23-24 has invited me to this event













FACTS




















Unveiling new tobacco products

E-cigarettes

Heated tobacco products















Unveiling new tobacco products

Types of e-cigarettes



Cigalike 1st generation



Vape Pen/E-go 2nd generation





MODs 3rd generation





Pod / Vape Pod 4th generation





Unveiling new tobacco products

Heated Tobacco Products











Tobacco products profile

	Cigarettes, Cigars, Pipes,	Electronic Cigarettes	Heated Tobacco Products
Combustion	Yes	No	No
Previous heating	-	No	Yes
Nicotine	Yes	Yes/No	Yes
Tobacco	Yes	No	Yes
Solid Waste	External	Intern	Intern
Mainstream smoke	Yes	Yes	Yes
Sidestream smoke	Yes	No	No
Produce/sustain addiction	Yes	Yes	Yes






Prevalence of smoking tobacco 2020 Cigarettes, cigars, cigarillos, pipes

23% smoke (3% points less than 2017)

22% used to smoke

55% have never smoked











Prevalence of smoking tobacco 2020 Cigarettes, cigars, cigarillos, pipes






















Electronic Cigarette Use in 12 European Countries: Results From the TackSHS Survey

Silvano Gallus¹, Alessandra Lugo¹, Chiara Stival¹, Sonia Cerrai², Luke Clancy³, Filippos T. Filippidis⁴, Giuseppe Gorini⁵, Maria José Lopez^{6,7,8,9}, Ángel López-Nicolás¹⁰, Sabrina Molinaro², Anna Odone^{11,12}, Joan B. Soriano^{13,14}, Olena Tigova^{14,15,16,17}, Piet A. van den Brandt^{18,19}, Constantine I. Vardavas^{20,21}, Esteve Fernandez^{14,15,16,17}, and the TackSHS Project Investigators*


Prevalence of use of e-cigs:

2.4% overall

2.5% in men and 2.3% in women

Ranged from:

0.6% in Spain to 7.2% in England



Gallus et al. J Epidemiol. 2021.





Pattern of use of e-cigs (%) used among current former users

59% of e-cig users and 79% of HTP users consume conventional products




Current smokers of conventional cigarettes have a higher prevalence of ever of ecigarettes ever use from 20.4% to 83.1%

DUAL or POLY-TOBACCO USERS





Drug and Alcohol Dependence 139 (2014) 60-70



Poly-tobacco use among adults in 44 countries during 2008–2012: Evidence for an integrative and comprehensive approach in tobacco control

Israel T. Agaku^{a,*}, Filippos T. Filippidis^a, Constantine I. Vardavas^a, Oluwakemi O. Odukoya^b, Ayodeji J. Awopegba^c, Olalekan A. Ayo-Yusuf^{a,d}, Gregory N. Connolly^a

Poly-tobacco users ...


- have an altered risk for tobacco-related morbidity and mortality
- are more likely to show stronger signs of nicotine dependence
- have higher cotinine levels and other toxicants (i.e., "dual use" of electronic cigarettes and traditional cigarettes)
- less likely to remain abstinent from tobacco after having attempted quitting








DESCRIPTION



FACTS







Some questions to consider regarding new tobacco products:

- Are they effective for quitting tobacco?
- Do they serve as a gateway to tobacco use, particularly among the youth?
- Are they safe, and what are the known health effects?"



Some questions to consider regarding new tobacco products:


- Are they effective for quitting tobacco?
- Do they serve as a gateway to tobacco use, particularly among the youth?
- Are they safe, and what are the known health effects?"







Meta-analysis association between e-cigarette use and quitting smoking










Meta-analysis pharmacotherapies and e-cigs (≥ 6 months abstinence)




Note, darker intervals represent CrI and lighter intervals represent PI. Control: no pharmacological or EC intervention. *Abbreviations* CrI: credibility interval; EC: e-cigarette; N: number of participants; OR: odds ratio; PI: prediction interval





Does this mean that we might recommend e-cigs to our patients who smoke?









Some questions to consider regarding new tobacco products:

- Are they effective for quitting tobacco?
- Do they serve as a gateway to tobacco use, particularly among the youth?
- Are they safe, and what are the known health effects?"





Why are they used among the youth?



CURIOSITY AND FLAVORS



ACCEPTANCE AND MARKETING



U

PERCEIVED HEALTH BENEFITS




CONVENIENCE AND STEALTH







Meta-analysis of longitudinal studies Risk of becoming smokers among e-cigarette young users



FACT

Electronic cigarettes
multiply by 3.7 the
risk of starting to
smoke and becoming
a daily smoker (young
adults)

Soneji et al., 2017





Some questions to consider regarding new tobacco products:

- Are they effective for quitting tobacco?
- Do they serve as a gateway to tobacco use, particularly among the youth?
- Are they safe, and what are the known health effects?"














Substance	Liquid 1	Liquid 2	Liquid 3	Liquid 4
Propylene glycol	85%	80%	90%	80%
Nicotine	1.6%	2.4%	3.2%	0.1%
Glycerol	2%	5%	-	5%
Tobacco essence	-	4%	4.5%	1%
Essence	2%	-	1%	1%
Organic acid	1%	-	-	2%
Anti-oxidation agent	1%	-	-	-
Butyl valerate	-	1%	-	-
Isopentyl hexonate	-	1%	-	-
Lauryl laurate	-	0.6%	-	-
Benzyl benzoate	-	0.4%	-	-
Methyl octynicate	-	0–5%	-	-
Ethyl heptylate	-	0.2%	-	-
Hexyl hexanoate	-	0.3%	-	-
Geranyl butyrate	-	2%	-	-
Menthol	-	0.5%	-	-
Citric acid	-	0.5%	2.5%	-
Water	-	-	-	2.9%
Alcohol	-	-	-	8%





Nicotine in EC and HTP aerosols compared to conventional cigarettes

		N of studies	Nicotine (mg) range
	Conventional cigarette	8	0,361 - 2,02
	IQOS	7	0,30 - 1,41
	Glo	1	0,462
	iFuse	1	0,358
	1st EC generation	1	0,86
	2nd EC generation	2	0,50 - 1,73
	3rd EC generation	1	1,84




Adapted from Simonavicius et al. Tob. Control. 2019.





Toxic levels (%) and compounds in HTP aerosols compared to a conventional cigarette.

	Heated Tobacco Products		
Compounds	IQOS (n=8)	Glo (n=3)	iFuse (n=1)
Acetaldehyde	12-22%	5%	<1%
Acrolein	6-82%	1-2%	5%
Amnonia Benzopyrene Crotonaldehyde Formaldehyde Nicotine Glycerol	33-38%	12-15%	<50%
	5-9%	2-3%	<7%
	4-6%	1-2%	<3%
	8-74%	6-7%	13%
	57-84%	18-23%	139%
	163-203%	101-129%	
Total Particular Matter	89-135%	54-56%	
Tar	33-79%	46-48%	



propylene glycol, carbonyls, metals







FACTS: E-cigs and HTP release toxic components

Important aspects it the study of causality:

- Difficult to establish causality due to several patterns of use (dual, poly-use)
- Stronger inhalation than conventional cigarettes
- Several toxic components in the aerosol (propylene glycol, carbonyls, metals)

Main adverse effects:

- In 2019 a new group of respiratory symptoms was reported: the vaping-associated lung injury (VALI) epidemic (wheezing, difficulty to breath, acute pneumonia in some cases)
- More frequent Irritation of the mouth and throat, dry mouth
- Increase in heart rate and blood vessel damage (risk of cardiovascular disease)

Specific in the lungs:

- Lung disease: VALI, chronic bronchitis, and asthma symptoms (double the risk).
- Unknown effect in the long term. Cancer? We don't know yet








DESCRIPTION



FACTS









Arguments in favor:				
Harm reduction	Favorable risk balance compared to smoking tobacco	Preferable to nicotine replacement therapy	Stimulates cessation	

Arguments against:				
Doubts about its safety	Delays /prevents cessation	Gateway to nicotine addiction	Undermin es achievem ents gained (e.g., smoke- free laws)	Aggressiv e marketing /unregula ted market











- The ways to consume tobacco and nicotine have evolved and diversified.
- More different products mean more complications for the study – poly-use.
- New tobacco products try to initiate (gateway) and maintain consumption
- Their usefulness for quitting smoking has been recently proven, but maintain addiction to nicotine and we do not know the consequences in the long term.
- The aerosols produced by new tobacco products constitute a new source of pollution (inflammatory effect on the lungs and risk of asthma exacerbation: VALI)
- Their long-term health effects are still unknown.





Does this mean that we might recommend e-cigs to our patients who smoke?



